We can't let perfection be the enemy of good
Medicine has long dreamed of a single, simple test that could see what the body conceals before symptoms speak. The NHS-Galleri trial — now past its final appointments and awaiting analysis — is testing whether one vial of blood can detect up to fifty cancers early enough to change outcomes. Results expected next year carry unusual weight: NHS leadership has signalled it will not repeat the historical pattern of letting successful science wait a decade before reaching patients.
- A blood test capable of identifying fifty different cancers at once could fundamentally alter how the NHS intercepts the disease — but only if the trial data holds up.
- Participants have completed their two-year appointment cycle, and the pressure now falls on the analysis: the findings expected next year will either accelerate or stall a potential transformation in cancer screening.
- Sir Harpal Kumar, president of Grail, is pushing hard against institutional inertia, warning that the old pattern of letting promising trial results gather dust for a decade cannot be allowed to repeat itself.
- NHS national cancer director Peter Johnson has offered cautious but genuine optimism, framing the technology as a possible solution to the stubborn challenge of catching cancer before it spreads.
- The trial is designed not to replace existing screening but to work alongside it — the question is whether adding this tool to mammography and colonoscopy finds cancers that would otherwise stay hidden until symptoms emerge.
A single vial of blood might soon become one of the NHS's most powerful tools against cancer. The NHS-Galleri trial is testing whether a blood test capable of detecting up to fifty different cancers could work alongside existing screening programs, catching malignancies early when treatment is most likely to succeed.
Participants attended three appointments over two years, and those appointments have now concluded. The NHS expects to release results next year — findings that could reshape how the health service approaches cancer detection across the country.
Sir Harpal Kumar, president of Grail, the company behind the Galleri test, spoke at a panel event about the urgency of moving from trial to implementation. He acknowledged the preliminary data looked promising, though not exceptional enough to justify an immediate large-scale pilot. But he pushed back against the traditional pace of medical adoption. "We can't do what we've done in the past, which is we get results from great trials and then it takes 10 years before we get to a decision to roll anything out," he said. He also cautioned against letting the pursuit of perfection obstruct progress, arguing that multi-cancer screening tests are coming regardless, and that the technology is already capable of detecting cancers that have never before been caught through screening.
Peter Johnson, the NHS's national cancer director, echoed that cautious optimism, describing the technology as promising and suggesting it might offer solutions to the persistent challenge of earlier diagnosis. Early detection remains one of oncology's most reliable levers for improving outcomes.
What happens next depends entirely on what the data shows. If the results justify it, the NHS has signalled it will move toward implementation faster than medical innovation typically allows. Either way, the conversation about multi-cancer blood screening has shifted from theoretical to imminent.
A single vial of blood might soon become one of the NHS's most powerful tools against cancer. The NHS-Galleri trial is testing whether a blood test capable of detecting up to 50 different cancers could work alongside the screening programs already in place, catching malignancies early when treatment is most likely to succeed.
The trial itself has reached a milestone. Participants were invited to attend three appointments spread across two years, and those appointments have now concluded. But the real work—analyzing what the blood samples reveal—is just beginning. The NHS expects to release results next year, and those findings could reshape how the health service approaches cancer detection across the country.
Sir Harpal Kumar, president of Grail, the company behind the Galleri test, has made clear that speed matters. Kumar, who spent seven years as chief executive of Cancer Research UK before his current role, spoke at a panel event about the urgency of moving from trial to implementation. He acknowledged the preliminary data from the first year looked promising, though not exceptional enough to justify launching a large-scale pilot program immediately. But he pushed back against the traditional pace of medical adoption. "We can't do what we've done in the past, which is we get results from great trials and then it takes 10 years before we get to a decision to roll anything out," he said. If the results prove positive, Kumar expressed hope the test could be deployed through the NHS without unnecessary delay.
Kumar also reframed the conversation around what "good enough" means. "I do think we're going to have to have multi-cancer screening tests," he said. "The good news is the technology is there. It's evolving and it's continuing to improve and it turns out that some of those are better at picking up cancers that we have never been able to pick up before." He cautioned against letting the pursuit of perfection become an obstacle to progress.
Peter Johnson, the NHS's national cancer director, echoed that cautious optimism. Speaking at the same event, Johnson described the technology as promising and suggested it might "offer us some solutions" to the persistent challenge of diagnosing cancer earlier in its course. Early detection remains one of oncology's most reliable levers for improving outcomes; a cancer caught in its earliest stages is far more treatable than one discovered after it has spread.
The trial itself was designed with a specific question in mind: can the Galleri blood test, used in tandem with existing screening programs like mammography and colonoscopy, help the NHS find more cancers at an earlier stage? The NHS website frames it plainly: the test works by identifying cancer-related signals in blood, and the hypothesis is that combining this new tool with established screening could catch diseases that might otherwise go undetected until symptoms appear.
What happens next depends on what the data shows. If the results justify it, the NHS could move toward implementation faster than medical innovation typically allows. If they fall short, the trial will have still advanced understanding of how this technology performs in a real health system. Either way, the conversation about multi-cancer blood screening has shifted from theoretical to imminent.
Notable Quotes
We can't do what we've done in the past, which is we get results from great trials and then it takes 10 years before we get to a decision to roll anything out.— Sir Harpal Kumar, president of Grail
The technology is promising and might offer us some solutions to boost early diagnosis.— Prof Peter Johnson, NHS national cancer director
The Hearth Conversation Another angle on the story
Why does it matter that this trial is ending now, when the results won't come until next year?
Because the appointments are done. The blood has been drawn. Now it's just analysis and waiting. But the fact that they're already talking about implementation timelines—that's the real signal. They're not treating this as a distant possibility.
Sir Harpal mentioned preliminary data was "promising but not exceptional." What does that distinction mean?
It means the first-year results were good enough to keep going, but not so overwhelming that they could skip straight to a nationwide rollout. They needed to see the full two years of data. It's the difference between "this looks like it might work" and "this definitely works."
He also said they can't let "perfection be the enemy of good." Is he pushing for a lower bar?
Not exactly. He's saying that if the results are solid—not perfect, but solid—the NHS should move faster than it has historically. The old pattern was: trial succeeds, then a decade passes before anyone actually uses it. He's arguing that's wasteful when lives are at stake.
What makes this different from existing cancer screening?
Existing screening targets specific cancers—mammograms for breast, colonoscopies for colon. This one test looks for signals from 50 different cancers in a single blood draw. It's meant to work alongside the existing programs, not replace them. It's an additional layer.
If it works, how quickly could people actually get access?
That's the open question. Kumar said he hopes it could be implemented "immediately" if results are positive. But "immediately" in NHS terms could still mean months of planning and rollout. Still, the intent is clearly to move faster than the old ten-year lag.